On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Similar Posts
KVK-Tech, Inc. Issues Voluntary Nationwide Recall of One Lot of Betaxolol Tablets, USP 10 mg (Batch Number: 17853A) as a Precautionary Measure Due to a Single Foreign Tablet Found During the Line Clearance After the Batch was Packaged
Newtown, Pennsylvania, KVK-Tech, Inc. is voluntarily recalling one lot (Batch Number: 17853A; “the batch”) of Betaxolol Tablets, USP 10 mg, White, Round, film coated biconvex tablets, debossed “K” above bisect “13” on one side and plain on the other side” to the consumer level. The batch was distribGeneric Drug Research Priorities & Projects
In accordance with the Generic Drug User Fee Amendments (GDUFA), FDA consults with industry and the public to create an annual list of regulatory science initiatives on generic drugs. These priorities are discussed and developed in public meetings and workshops, resulting in several awarded projectsFDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury
FDA is warning that getting alcohol-based hand sanitizer in the eyes can cause serious injury. If this occurs, immediately rinse with running water for 15 to 20 minutesUpdated Release: Southwind Foods, LLC Recalls Frozen Shrimp Because of Possible Health Risk
Southwind Foods, LLC of Carson, California is voluntarily recalling a limited quantity of Frozen Shrimp, due to possible radionuclide (Cesium-137) contamination. Cs-137 is a man-made radioisotope of cesium. Traces of Cs-137 are widespread and can be present in the environment at background levels, aHorizon Tool Inc. – 706567 – 06/06/2025
CGMP/Finished Pharmaceuticals/AdulteratedFDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program
ISTAND supports innovative, science-driven approaches that improve drug development and regulatory decision-making, ultimately helping to make therapies available to address patients’ unmet needs.
